NEW YORK (360Dx) – An allele-specific multiplex sequencing (ASMS) assay that can identify low concentrations of relevant drug targets could provide clinical support in identifying and prescribing appropriate chemotherapeutic drugs, and it has potential for routine clinical use in a far broader scope of applications, according to its developer MultiGen Diagnostics.
Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.